Burak Cem – VP & General Manager, Novo Nordisk Turkey
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Address: Nispetiye Caddesi, Akmerkez, E3 Blok, Kat:7 Etiler, Istanbul, Turkey 34335, Turkey
Tel: +90 212 3854040
Web: http://www.novoturk.com/documents/home_page/document/index.asp
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in 190 countries.
Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Providing solutions mainly in Diabetes and Haemophilia
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Novo Nordisk Turkey has taken a degree of leadership by working to facilitate and encourage cooperation and collaboration between different stakeholders in the diabetes management ecosystem. For general manager Şebnem…
Would you like to provide our international readers with a brief introduction into Novo Nordisk’s Turkish affiliate? As you may know, Novo Nordisk has a rich history of over 85…
Keyman’s general manager discusses his firm’s development efforts towards vaccine production, in conjunction with TUBITAK and Hacettepe University, and their geographic expansion into Africa, Latin America, and Southeast Asia. Please…
A recent arrival from China, Lilly’s Turkey MD Daniel Lucas assesses the country’s healthcare system and raises key questions about the sustainability of the system at large going forward, and…
MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy…
GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in…
Imuneks is currently operating in the OTC market, but with three supergeneric products ready to market on the RX side, the firm has the potential to soon become one of…
Recordati’s South East regional VP, based in Istanbul, discusses Recordati Turkey’s key role as a manufacturing hub for Recordati, the importance of the Turkish market (fourth largest globally for the…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted…
The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great…
Turkey’s leading pharmaceutical company is in the process of developing production facilities abroad, and it has just begun construction of a USD 100 million biotech facility; CEO Süha Taşpolatoğlu believes…
The leadership of Turkey’s newest major pharmaceutical player, Pharmactive, discuss the firm’s two pronged growth strategy, detailing their own sales objectives and prospects, as well as the opportunities that they…
Polifarma is Turkey’s largest producer of basic parenteral IV solutions with a 41 percent market share the country and growing exports across the region. According to the Chairman and CEO…
See our Cookie Privacy Policy Here